Fabry disease

Non-industry sponsored (local) studies:

• The NeuroFab study: Two year follow-up of Cognitive and Psychological functioning in patients with Fabry Disease
• Cerebral manifestations on MRI-brain
• Overcoming the negative effect of anti αGAL antibody formation in Fabry disease
• The Fabry Cardio Prediction Study

Multicenter clinical trials the AMC participates in:

• Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function (BALANCE)
• Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL (R) (Agalsidase Alfa)

• Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease (MODIFY)